Search
Rovatirelin
go.drugbank.com/drugs/DB15338InvestigationalRovatirelin is under investigation in clinical trial NCT01384435 (A Phase II Double Blind Comparative Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)).
Gosuranemab
go.drugbank.com/drugs/DB15376InvestigationalGosuranemab is under investigation in clinical trial NCT02460094 (Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy).
Disaccharide tripeptide glycerol dipalmitoyl
go.drugbank.com/drugs/DB15423InvestigationalDisaccharide tripeptide glycerol dipalmitoyl is under investigation in clinical trial NCT00003667 (Combination Chemotherapy and Biological Therapy in Treating Patients With High-Risk Ewing's Sarcoma).
GSK2798745
go.drugbank.com/drugs/DB16033InvestigationalGSK2798745 is under investigation in clinical trial NCT03372603 (A Study to Assess the Effectiveness and Side Effects of GSK2798745 in Participants With Chronic Cough).
FF-10101-01
go.drugbank.com/drugs/DB16050InvestigationalFF-10101-01 is under investigation in clinical trial NCT03194685 (Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia).
Darovasertib
go.drugbank.com/drugs/DB16059InvestigationalIDE-196 is under investigation in clinical trial NCT03947385 (Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions).
Bemarituzumab
go.drugbank.com/drugs/DB16105InvestigationalBemarituzumab is under investigation in clinical trial NCT03694522 (A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (Mfolfox6) in Gastric/gastroesophageal Junction Cancer (FIGHT)).
Uproleselan
go.drugbank.com/drugs/DB14829Investigationalin AML). … Uproleselan is a novel, specific E-Selectin antagonist under investigation in clinical trial NCT02306291 (Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy
Categories: E-Selectin, antagonists & inhibitorsLerociclib
go.drugbank.com/drugs/DB16218InvestigationalLerociclib is under investigation in clinical trial NCT02983071 (G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-positive, Her2-negative Locally Advanced or Metastatic Breast
EB05
go.drugbank.com/drugs/DB16477InvestigationalEB05, in combination with standard of care (SOC), is being investigated in clinical trial NCT04401475 to evaluate its safety and efficacy in adult hospitalized patients with COVID-19 and ARDS.